Can Cutting-edge Tech Reduce Rising CVD Burden?
BioSpectrum Asia|BioSpectrum Asia Dec 2023
Each year World Heart Day is observed to increase awareness about cardiovascular diseases (CVDs), after all defeating them is something that matters to every beating heart. CVDs are disorders of the heart and blood vessels and are often referred to as “silent killers” because most of the patients with underlying heart ailments do not exhibit any obvious symptoms. Development and deployment of cutting-edge technologies backed by requisite government policy support and direction will help in bolstering the fight against CVDs and thus improving the quality of the individuals’ heart and also their lives. Let’s take a closer look.
Can Cutting-edge Tech Reduce Rising CVD Burden?

India is rapidly becoming the global CVDs epicentre which is primarily attributed to a mix of genetics, poor cultural practices and lifestyle factors among Indians such as increased trans fatty acids content in foods due to repeated use of cooking oil, unique pattern of atherogenic dyslipidaemia, consumption of processed and read-to eat foods, physical inactivity, obesity, high tobacco use, and increased stress levels that have contributed towards the increased prevalence of CVDs.

According to the Lancet’s Global Burden of Disease study, India has an age-standardised CVD death rate of 282 per 100,000 population which is remarkably higher than the global average of 233 deaths per 100,000. The key to managing CVDs is early detection which can help identify the risk of cardiovascular diseases before it becomes too late. The industry is making tremendous efforts to reduce the disease burden, technology advancements in digital health and MedTech have enabled disease detection at an early stage, and also helped disease management of high-risk patients.

Technologies such as artificial intelligence (AI)based medical imaging analysis and precise screening solutions, continuous monitoring wearables and digital therapeutics have emerged as key enablers for the prevention and management of CVD in India. These technologies can play a vital role in lowering CVD risk and reducing the associated mortality rate which is especially important for a country that accounts for 60 per cent of the world’s disease burden. Some of these technologies to reduce cardiac disease burden are given below.

AI-based medical imaging analysis and screening solutions

この記事は BioSpectrum Asia の BioSpectrum Asia Dec 2023 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は BioSpectrum Asia の BioSpectrum Asia Dec 2023 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

BIOSPECTRUM ASIAのその他の記事すべて表示
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024